anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine for treating recurrent aphthae, which comprises the following medicines in parts by weight: 50-200 parts of rheum officinale, 80-400 parts of as arum, 70-300 parts of jasmine, 20-200 parts of turmeric, 50-300 parts of scutellaria baicalensis, 50-200 parts of golden cypress, 30-200 parts of ephedra and 300-700 parts of gypsum. The raw materials are processed to obtain the traditional Chinese medicine for treating the recurrent aphthae and are pure traditional Chinese medicine preparations. The traditional Chinese medicine for treating the recurrent aphthae has the advantages of abundant medicine source, low price, convenience in taking, safety and no toxin, and no patients suffer from anaphylactic reaction or side effect when the traditional Chinese medicine is primarily used in clinic. Meanwhile, the traditional Chinese medicine is very suitable for emergency during a business trip or travel. The traditional Chinese medicine has the advantages of small dosage and small side effect. The clinic research and the previous retrospective study of the traditional Chinese medicine indicate that the preparation has a good clinic curative effect, extremely high clinic value, bright prospect on treating the recurrent aphthae, wide abroad market and good development prospect, and obvious social benefit and economic benefit can be obtained after the traditional Chinese medicine is popularized and utilized.
FIELD: cosmetics. SUBSTANCE: invention relates to production of agents used for hair care. Method of preparing hair lacquer involves the preparing lacquer base by mixing film-forming substances with the main solvent followed by cooling and addition of biologically active components and perfume to the lacquer base. Before addition to the lacquer base the biologically active components are mixed with binar mixture of solvents consisting of the main solvent and additional solvent that forms the molecular solution with biologically active components. Binar mixture of ethanol and diethyl ether is used in the use of CO 2 -extracts of vegetable raw as a source of biologically active components. Method provides to prepare lacquer with high vitaminizing activity. EFFECT: improved method of preparing, enhanced quality of lacquer. 4 cl
Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
Mckenzie exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
The present invention makes use of Chinese herbal medicine such as lives radix astragali 40g, root of rehmannia 30g, Huai Chinese yam 30g, scrophularia buergeriana 35g, Huang Qin 15g, Chinese goldthread rhizome 15g, rhizome of Ligusticum wallichii 15g, corktree 15g, herbaceous peony 15g, dark green technique 20g, Shan Qi child 20g, fu qin Chinese medicine 20g, Chinese angelica 20g, fresh oyster 50g and so on to boil tisane, tea and health-care drinks. Or the above Chinese medicine configuration are used to make the pill, the pellet, the injection, the medicinal powder, the oral, the aerosol, the oil emulsion, the sponginum, and the capsule. The present invention has new use of treating diabetes. The present invention mainly treats diabetes, nourishing body's essential fluid, invigorating Qi and Clear away heat and toxic materials. The present invention is suitable in diabetes merge alkone sickness. Add the dried orange peel, the pinellia, bamboo shavings and herb of fortune eupatorium for patients who are with nausea anesthesia. Add the prunella vulgaris, the hook cane, the fresh keel, and the chrysanthemum for patients who are with dizziness and headache. The seed of feather cockscomb, the fruit of the Chinese wolfberry, the grass cassia tora, chong the luxuriant child are added for patients who are with blurred vision. The gypsum, common anemarrhena rhizome, the root of trichosanthes kirilowii, and the sea clam meal thirstily are added for patients who are with drinking inordinately. The oldenlandia diffuse and heavy Astragals Root are added for patients who are with albumen in the emiction. The curcuma, the stone calamus and the Senega Root are added for patients who are with deeply addicted to sleeping.
Robotic devices are commonly used to quantify sensorimotor function of the upper limb after stroke; however, the availability and cost of such devices make it difficult to facilitate implementation in clinical environments. Tablets (e.g. iPad) can be used as devices to facilitate rehabilitation but are rarely used as assessment tools for the upper limb. The current study aimed to implement a tablet-based Maze Navigation Task to examine complex upper-limb movement in individuals with chronic stroke. We define complex upper-limb movement as reaching movements that require multi-joint coordination in a dynamic environment. We predicted that individuals with stroke would have more significant spatial errors, longer movement times, and slower speeds compared to controls with increasing task complexity. Twenty individuals with chronic stroke who had a variety of arm and hand function (Upper extremity Fugl-Myer 52.8 ± 18.3) and twenty controls navigated eight pseudorandomized mazes on an iPad using a digitizing stylus. The task was designed to elicit reaching movements engaging both the shoulder and elbow joints. Each maze became increasingly complex by increasing the number of 90° turns. We instructed participants to navigate each maze as quickly and accurately as possible while avoiding the maze's boundaries. Sensorimotor behavior was quantified using the following metrics: Error Time (time spent hitting or outside boundaries), Peak Speed, Average Speed, and Movement Time, Number of Speed Peaks. We found that individuals with stroke had significantly greater Error Time for all maze levels (all, p < 0.01), while both speed metrics, Movement Time and Number of Speed Peaks were significantly lower for several levels (all, p < 0.05). As maze complexity increased, the performance of individuals with stroke worsened only for Error Time while control performance remained consistent (p < 0.001). Our results indicate that a complex movement task on a tablet can capture temporal and spatial impairments in individuals with stroke, as well as how task complexity impacts movement quality. This work demonstrates that a tablet is a suitable tool for the assessment of complex movement after stroke and can serve to inform rehabilitation after stroke.
Significant increase in drug exposures occurred when tenofovir disoproxil fumarate tablets were administered to subjects with moderate to severe renal impairment (creatinine clearance below 50 mL/min). Table 3 provides dosage interval adjustment for patients with renal impairment. No dosage adjustment of tenofovir disoproxil fumarate tablets 300 mg is necessary for patients with mild renal impairment (creatinine clearance 50–80 mL/min) [see Warnings and Precautions (5.3), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].   
Table 3 Dosage Interval Adjustment for Adult Patients with Altered Creatinine Clearance

a. Calculated using ideal (lean) body weight.   
b. Generally once weekly assuming 3 hemodialysis sessions a week of approximately 4 hours' duration. Tenofovir disoproxil fumarate should be administered following completion of dialysis.  
No data are available to make dosage recommendations in patients with creatinine clearance below 10 mL/min who are not on hemodialysis.  
No data are available to make dosage recommendations in pediatric patients with renal impairment.
With the aging of the HIV-infected population in the United States and elsewhere, neurocognitive dysfunction will likely become an increasingly common problem. Older individuals could be at increased risk for efavirenz-associated adverse effects due to impaired metabolism, increased drug-drug interactions, and lower physiologic reserve, but there are few data on the long-term safety of efavirenz (and other antiretrovirals) in older individuals with HIV.

The Stanford HIV Aging Cohort (SHAC) is an ideal setting to study potential neurologic effects of antiretrovirals in aging patients. SHAC is an ongoing longitudinal study initiated in 2008 to evaluate aging in virologically-suppressed HIV-infected individuals. The cohort is supported through multiple grants including a grant from the State of California's HIV Research Program as well as a NIH supplemental grant. As of September 2013, approximately 150 virologically-suppressed HIV-infected adults have been enrolled. In addition to enrolling patients with good adherence to ART, the cohort purposefully excludes subjects with active substance abuse, unstable medical conditions, and psychiatric illnesses to limit potential confounding the study end points. Recently, an NIH supplemental grant (AI069556) was received which will expand the SHAC to 300 HIV-infected subjects. The median age of the subjects in the cohort is in the mid-50's allowing an ample number of older subjects for our planned studies.
The subject invention concerns materials and methods for providing for cone cell specific expression of a polynucleotide in a human or animal. One aspect of the invention concerns a polynucleotide promoter sequence that directs expression of an operably linked polynucleotide in cone cells. In one embodiment, a polynucleotide of the invention comprises a nucleotide sequence of an interphotoreceptor retinoid-binding protein (IRBP) gene that is positioned upstream of a promoter nucleotide sequence of a cone transducin alpha-subunit (GNAT2) gene. Another aspect of the subject invention concerns methods for expressing a selected polynucleotide in cone cells. The selected polynucleotide can be provided in a polynucleotide of the invention wherein the selected polynucleotide is operably linked to a polynucleotide promoter sequence of the invention. In one embodiment, the selected polynucleotide sequence is provided in a polynucleotide vector of the invention. The vector comprising the selected polynucleotide is then introduced into a cell. The selected polynucleotide is expressed only in cone cells, with very little, if any, expression in rods or other cells. A selected polynucleotide can be one that encodes, for example, a therapeutic protein or a functional protein that is defective or underexpressed in the targeted cone cells.
BACKGROUND: Incisional negative pressure wound therapy (iNPWT) is an adjunctive treatment that uses constant negative pressure suction to facilitate healing. The utility of this treatment modality on vascular operations for critical limb-threatening ischemia (CLTI) has yet to be elucidated. This study compares the incidence of postoperative wound complications between the Prevena Incision Management System, a type of iNPWT, and standard wound dressings for vascular patients who also underwent plastic surgery closure of groin incisions for CLTI.
METHOD: We performed a retrospective cohort study of 40 patients with CLTI who underwent 53 open vascular surgeries with subsequent sartorius muscle flap closure. Patient demographics, intraoperative details, and wound complications were measured from 2015 to 2018 at the University of California San Francisco. Two cohorts were generated based on the modality of postoperative wound management and compared on wound healing outcomes.
RESULTS: Of the 53 groin incisions, 29 were managed with standard dressings, and 24 received iNPWT. Patient demographics, comorbidities, and operative characteristics were similar between the 2 groups. Patients who received iNPWT had a significantly lower rate of infection (8.33% vs 31.0%, P = 0.04) and dehiscence (0% vs 41.3%, P < 0.01). Furthermore, the iNPWT group had a significantly lower rate of reoperation (0% vs 17.2%, P = 0.03) for wound complications within 30 days compared with the control group and a moderately reduced rate of readmission (4.17% vs 20.7%, P = 0.08).
CONCLUSIONS: Rates of infection, reoperation, and dehiscence were significantly reduced in patients whose groin incisions were managed with iNPWT compared with standard wound care. Readmission rates were also decreased, but this difference was not statistically significant. Our results suggest that implementing iNPWT for the management of groin incisions, particularly in patients undergoing vascular operations for CLTI, may significantly improve clinical outcomes.
This single center trial will be double-blind, controlled randomized with a crossover trial. One group (n=10) will start the study with the consumption of a Fe-54 salt fortified dairy product, while the other group will start the study with the consumption of Fe-57 salt fortified dairy product. The day after, in a cross over design, subjects will be administered the alternative test product. A blood sampling will be performed 14 days after the last stable isotope administration to allow the measurement of Fe stable isotope ratios and the calculation of Fe absorption. The duration of the trial will be 16 days in total.

The total sample size is 20 enrolled subjects. Patients will be healthy females aged 18-40 years old
Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
BACKGROUND: A juxtarenal abdominal aortic aneurysm is defined as a short (less than 4 mm) or no-neck aneurysm, which is often treated with open or complex endovascular repair. The evidence to support the best treatment strategy is scarce. The aim of this study was to assess the short- and mid-term outcomes of elective open surgical repair or fenestrated endovascular aneurysm repair for juxtarenal abdominal aortic aneurysms in Sweden.
METHODS: Patients who underwent elective open surgical repair or fenestrated endovascular aneurysm repair for juxtarenal abdominal aortic aneurysms between 2018 and 2021 were identified in the Swedish Vascular Registry. Demographics, practice patterns, and operative details were assessed. The primary outcome was 30-day mortality. Secondary outcomes included perioperative complications and mid-term survival.
RESULTS: Among 3777 aortic aneurysm repairs performed, 418 involved juxtarenal abdominal aortic aneurysms (open surgical repair 228 (54.5%), fenestrated endovascular aneurysm repair 176 (42.1%), chimney endovascular aneurysm repair 6 (1.4%), and branched endovascular aneurysm repair 8 (1.9%)). Some 25 centres performed juxtarenal abdominal aortic aneurysm repairs with open surgical repair and fenestrated endovascular aneurysm repair. The caseload varied from 2 to 54 repairs per centre. The mean aneurysm diameter was 61 mm. Endovascularly treated patients were older and had more pulmonary co-morbidities. The 30-day mortality rate was 2.2% (open surgical repair 2.6% and fenestrated endovascular aneurysm repair 1.7%; P = 0.397). Perioperative major complications occurred in 14.1% of patients (open surgical repair 19.3% and fenestrated endovascular aneurysm repair 7.4%; P < 0.001) and perioperative vascular complications occurred in 12.1% of patients (open surgical repair 8.8% and fenestrated endovascular aneurysm repair 11.9%; P = 0.190). The survival rate (estimated using Kaplan-Meier analysis) at 1 year and 3 years was 93.1% and 85.9% respectively for open surgical repair and 95.2% and 80.9% respectively for fenestrated endovascular aneurysm repair (P = 0.477).
CONCLUSION: This nationwide study reveals considerable variations in volume and treatment strategy between Swedish centres performing juxtarenal abdominal aortic aneurysm repairs. Survival is comparable for open surgical repair and fenestrated endovascular aneurysm repair, although there are significant baseline demographic differences between patients selected for the two treatment modalities.
Using an isolated nucleic acid comprising a sequence encoding a half transporter protein of the ABCG-family, in gene therapy methods, and in selecting somatic mammalian cells using at least one drug transportable by the transporter protein, is new. Independent claims are also included for: (1) a vector for gene transfer into a mammalian cell, comprising the nucleic acid; (2) selecting somatic mammalian cells using at least one drug transportable by the transporter protein; (3) somatic mammalian cells transformed by the vector; (4) an infectious virion obtainable from a viral vector; and (5) a pharmaceutical kit comprising the vector. ACTIVITY : Immunosuppressive. No biological data given. MECHANISM OF ACTION : Gene therapy; Hematopoietic cell protector. After retroviral transduction the cells were exposed to 5mM Mitoxanthrone (MX) selection for 3 days and induced for granulocyte differentiation by G-CSF, or plated directly in a colony forming assay and selected by MX in methylcellulose. Normal or mock transduced CD34+ cells did not show measurable MX extrusion capacity, but a significant increase in MX extrusion was seen in the ABCG2-G transduced progenitor cells, and this extrusion was further increased by MX selection of the transduced cells. When MX was used as a selection agent the mock transduced cells did not form colonies, while the MX selection decreased the number in the ABCG2-G transduced cells by about 50%. This reduction closely corresponds to the elimination of the cells not expressing ABCG2-G.
The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of contacting the oil or fat to a carboxymethyl cellulose or an ion exchange resin. The carboxymethyl cellulose can be a Blanose® cellulose gum and the resin can be a cationic resin. A deodorized vegetable oil or fat and a food product made there from is described. The food product can be an infant formula. It exhibits low levels of bound MCPD and/or low level of bound 3-MCPD. In one embodiment the oil or fat has a reduced level of free fatty acid as well as a limpid aspect and no off-flavors.
An apparatus for dispensing medications comprises: a portable cassette 100 with a body portion (102, fig. 2) including a plurality of compartments (106, fig. 3) and at least one displaceable lid 104; a sensor (108, fig. 5) configured to detect when a lid is displaced; a memory (110) and a first processor (112) configured to store, in the memory, respective times for each detection of displacement of the lid. A method of dispensing medicines using this dispenser is also claimed. Also claimed is an apparatus for dispensing medications, comprising a portable cassette with a body portion and lid as above, as well as a pill-dispenser (202, fig. 7) including: at least one dispensing compartment (204) arranged to store pills; a dispensing element (208) configured to release the pills from the compartment; and a cassette element (210) arranged to receive the portable cassette and displace it so that at least one pill falls into each cassette compartment. After the pills fall into the compartments, the portable cassette is removable from the pill dispenser, and the lid is displaceable to control access to the cassette compartments. Further apparatus and methods are also claimed.
Through experimental design and quantitative research methods. This experiment will test the effectiveness of the training method by intervening in the selective fitness, skills, and tactical performance of college students using a high-intensity interval training method on the ice. The experiment will use 12 weeks of high-intensity interval training to improve the fitness, skills, and tactical performance of the intervention for ice hockey players. The experiment consists of two groups, with 20 students in the experimental group and 20 students in the control group, to compare the differences between the two groups. The experiment was divided into a discussion group and a general teaching group. The purpose of this experiment is to provide a theoretical basis for the improvement of ice hockey training methods so that college ice hockey players can obtain better competitive performance, especially in physical fitness and technique.

The experimental group (1-12 weeks) performed repeated sprint training, sprint interval training (on-ice 45-s shift length conditioning drill), a long-pass tracking drill, and a chase-the-rabbit tracking drill. There are three phases: 1-4 weeks, 5-8 weeks, and 9-12 weeks, gradually increasing the intensity of training. Similarly, the control group performed varied-pace skating (1 minute accelerated skating, 2 minutes even pace), dribbling and shooting drill (30 m), passing-catching drill (20 m), and 2 on 1 offensive drill (full rink). As in the experimental group, the same three phases were used to gradually increase the intensity.
PROBLEM TO BE SOLVED: To obtain a microgel having a particle diameter of a specified or smaller value and being useful as a thickening agent having high thickening performances in an electrolyte solution, a dispersion stabilizer or a lubricant by crosslinking a (meth)acrylate polymer comprising N-vinylalkylamide units and oxyethylene glycol units with a crosslinking agent. SOLUTION: The crosslinked N-vinylcarbonamide resin is one obtained by crosslinking a polymer comprising compounds of formulas I and II (wherein R<1> to R<5> are each H, methyl or ethyl; X is a 2 or 3 alkylene; and n is 2-30) in a weight ratio I/II of (70-99.9)/(30-0.1) with a crosslinking agent and being in the form of microparticles having a mean particle diameter of 10μm or below. The compound of formula I is particularly desirably N-vinylacetamide. The compound of formula II is desirably one of the formula (wherein X is an ethylene group), especially methoxypolyethylene glycol methacrylate. The crosslinked agent used is desirably e.g. trimethylolpropane diallyl ether which is a compound having at least two ethylenic unsaturations. The microparticulate resin can be desirably obtained by a precipitation polymerization process.
To provide methods for treating cancer, or preventing cancer recurrence or progression.SOLUTION: Provided are methods for treating cancer, or preventing cancer recurrence or progression. The methods comprise administering to a patient in need thereof i) a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, and ii) an anti-CD38 antibody. Also provided is a use of a proteasome inhibitor of formula (I) or a pharmaceutically acceptable salt thereof. The proteasome inhibitor of formula (I) or a pharmaceutically acceptable salt thereof is administered with an anti-CD38 antibody for treating cancer in a patient in need thereof. Further provided is a therapeutic combination comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an anti-CD38 antibody. In the formula, Z1 and Z2 are each independently hydroxyl; or Z1 and Z2 together form a cyclic boronic ester having 2-20 carbon atoms, and optionally one or more heteroatoms selected from N, S, or O.SELECTED DRAWING: None